novel combinations in mrcc: axi/pembro vs axi/avelumab
Published 5 years ago • 762 plays • Length 10:15Download video MP4
Download video MP3
Similar videos
-
1:00
pembrolizumab/axitinib and avelumab/axitinib combo for rcc
-
1:38
dr. choueiri on avelumab plus axitinib in mrcc
-
9:05
mrcc: when is tki/i-o combination therapy appropriate?
-
1:37
dr. shuch on caveats of avelumab/axitinib combination in rcc
-
1:04
dr. rini discusses pembrolizumab plus axitinib in mrcc
-
7:36
mrcc patient selection for ipilimumab/nivolumab
-
3:10
keynote-426 rationale and results: pembro plus axitinib vs. sunitinib in mrcc
-
2:06
updated analysis of keynote-426: pembro plus axitinib vs sunitinib in mrcc
-
4:00
cancer immunotherapy - pd-1 and pd-l1
-
2:12
cancer immunotherapy | the pd-l1 pathway
-
1:06:04
itp: novel treatments
-
3:18
exploring the combination of first-line avelumab/axitinib in hcc
-
4:49
pembrolizumab plus axitinib and the future of further-line mrcc treatments
-
4:40
pembrolizumab plus axitinib in the second-line and beyond for mrcc
-
1:03
dr. rini on managing the toxicity of pembrolizumab plus axitinib in mrcc
-
0:57
avelumab and axitinib for the treatment of advanced rcc
-
2:27
combining avelumab and axitinib in advanced renal cell carcinoma (rcc)
-
1:47
dr. choueiri discusses avelumab/axitinib data in rcc
-
3:43
the rationale behind combination therapy in mrcc
-
7:49
immunotherapeutic combinations for mrcc: immotion-151
-
1:17
dr. vaishampayan on axitinib plus pembrolizumab in advanced rcc
-
4:47
keynote-426 - pembrolizumab plus axitinib versus sunitinib for mrcc